|Overview of Secondary PH/PAH
PH Secondary to MCTD
|PH Secondary to Pulmonary Fibrosis
PH Secondary to Scleroderma
PH Secondary to Scleroderma: Dyspnea
When PH occurs along with other lung, heart, or systemic connective tissue disease (such as scleroderma), it is called Secondary Pulmonary Hypertension. The distinction is important because treatments, and their effectiveness, can vary depending upon whether the pulmonary hypertension is primary or secondary.
"Listen to the Patient" Anticoagulation Is Critical in the Antiphospholipid (Hughes) Syndrome (APS). Affecting, almost uniquely, both veins and arteries, the clinical features (of APS) range through deep vein thrombosis (DVT), chronic leg ulcers, recurrent miscarriages, headache, heart attacks, renal vein and artery thrombosis, to pulmonary embolism and even pulmonary hypertension. The Journal of Rheumatology. (Also see Antiphospholipid Syndrome, Leg Ulcers, Pregnancy and Scleroderma, and Cardiac Involvement)
Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort. Results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. The prevalence of PH is much lower than expected from previous studies but confirm the seriousness of the disease complication. Rheumatology (Oxford), 2013 Feb 12.
Pulmonary Fibrosis. Pulmonary Hypertension can occur in pulmonary fibrosis, even without severe lung dysfunction or hypoxemia (low oxygen in the blood.) ISN.
|Living with PF
Prediction Of Pulmonary Hypertension Related To Systemic Sclerosis (SSc) By An Index Based On Simple Clinical Observations. Using routine clinical observations, we developed a simple score, which accurately predicted the risk of PH in SSc. C. Meune. EULAR 2011 OPO196. Ann Rheum Dis 2011;70(Suppl3):135.
PH (Pulmonary Hypertension) and Scleroderma. In scleroderma, 10–15% of patients have evidence of pulmonary arterial hypertension and another 10–15% of patients have pulmonary hypertension as a complication of interstitial lung disease and/or left ventricular dysfunction. Pulmonary Hypertension Society, 2010.
Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. A majority of patients with mildly symptomatic systemic sclerosis and pulmonary arterial hypertension in NYHA FC II at diagnosis have a severe disease with poor prognosis. Rheumatology, Feb 2010.
Diagnosis and Management of Pulmonary Hypertension in Systemic Sclerosis. Patients with systemic sclerosis (SSc) can develop pulmonary hypertension (PH) caused by pulmonary arterial hypertension (PAH), left ventricular disease, or pulmonary fibrosis. Prognosis and therapeutic response are worse in PAH-SSc than in other PAH categories (median survival, 1–3 yr). Current Rheumatology Reports, Volume 12, Number 1 / February, 2010. (Also see Cardiac Involvement and Pulmonary Fibrosis)
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, Volunteer, or Donate.
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report or update any page content or links.
Toll Free US/Canada Scleroderma Hotline: 800-564-7099